Regenxbio, a Washington, DC-based gene therapy biotech company, closed $30m in Series C funding.
The round was led by Venrock and Brookside Capital with participation from Deerfield Management, FoxKiser and Fidelity BioSciences. In conjunction with the funding, Camille Samuels, a partner at Venrock and Michael Gelman joined Regenxbio’s board of directors.
The company intends to use the funds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, and expand its team.
Led by Ken Mills, President and CEO, Regenxbio, is leveraging its proprietary NAV® Technology to develop treatments for central nervous system (CNS) diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II), as well as other diseases in which gene therapy can make a meaningful difference in patients’ lives.
Together with Fidelity Biosciences, the company formed Dimension Therapeutics, which is focused on the development and commercialization of NAV-based gene therapies for liver-directed rare diseases.